Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease

Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1266 - 1273 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5432 İndeks Tarihi: 26-12-2022

Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease

Öz:
Background/aim: Clinical exacerbations characterized with neurological symptoms are observed in around 10% of Behçet’s disease (BD) patients and may culminate in severe disability. Although certain immunological factors have been associated with disease activity in neuro-Behçet’s disease (NBD), biomarkers for monitoring the clinical outcome of NBD have not been properly investigated. Materials and methods: Levels of neurofilament light chain (NFL), homeobox protein Hox-B3 (HoxB3), and YKL-40 were measured in cerebrospinal fluid (CSF) samples of 23 parenchymal (n = 16) and nonparenchymal (n = 7) NBD patients obtained during NBD attacks by ELISA. Parameters of clinical progression and outcome were assessed for an average follow-up period of 3.9 ± 1.3 years. Results: Parenchymal NBD patients showed elevated CSF levels of NFL, HoxB3, and YKL-40 as compared to nonparenchymal patients. NBD patients showing an increase in modified Rankin score (mRS) values during follow-up had significantly higher CSF NFL levels. Patients with relatively lower CSF NFL levels (<1000 ng/L) did not develop attacks or cognitive impairment interfering with daily life activities during follow-up. NFL levels correlated with disease duration and mRS at the last follow-up visit, while HoxB3 levels correlated with a number of attacks during follow-up. Conclusion: CSF level of NFL appears to predict the prospective somatic and cognitive disability in NBD patients and may thus be potentially used as a biomarker of clinical outcome in this disease.
Anahtar Kelime: Neurofilament light hoxB3 ykl-40 neuro-Behçet prognosis

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Leccese P, Alpsoy E. Behçet’s Disease: An Overview of Etiopathogenesis. Frontiers in Immunology 2019; 10: 1067. doi: 10.3389/fimmu.2019.01067
  • 2. Totsuka S, Hattori T, Yazaki M, Nagao K, Mizushima S. Clinicopathologic studies on neuro-Behçet’s disease. Folia Psychiatrica et Neurologica Japonica 1985; 39: 155-166. doi: 10.1111/j.1440-1819.1985.tb02899.x
  • 3. Arai Y, Kohno S, Takahashi Y, Miyajima Y, Tsutusi Y. Autopsy case of neuro-Behçet’s disease with multifocal neutrophilic perivascular inflammation. Neuropathology: Official Journal of the Japanese Society of Neuropathology 2006; 26: 579-585. doi: 10.1111/j.1440-1789.2006.00734.x
  • 4. Kürtüncü M, Tüzün E, Akman-Demir G. Behçet’s Disease and Nervous System Involvement. Current Treatment Options in Neurology 2016; 18: 19. doi: 10.1007/s11940- 016-0405-6
  • 5. Acar-Özen NP, Tuncer A. Prognosis of Neuro-Behçet’s Syndrome. In: Tüzün E, Kürtüncü M (editors): Neuro-Behçet’s Disease. Springer, Cham 2021: 151-162.
  • 6. Takahashi S, Sanjo N, Miyamoto S, Hattori T, Oyama J et al. Width of the third ventricle as a highly-sensitive biomarker in chronic progressive neuro-Behçet’s disease. Journal of the Neurological Sciences 2020; 421: 117284. doi: 10.1016/j.jns.2020.117284
  • 7. Liu J, Yan D, Wang Z, Yang Y, Zhang S et al. Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet’s syndrome: case series and literature review. Therapeutic Advances in Musculoskeletal Disease 2020; 12: 1759720X20971908. doi: 10.1177/1759720X20971908
  • 8. Ben Dhifallah I, Borhani-Haghighi A, Hamzaoui A, Hamzaoui K. Decreased Level of IL-37 Correlates Negatively with Inflammatory Cytokines in Cerebrospinal Fluid of Patients with Neuro-Behçet’s Disease. Iranian Journal of Immunology: IJI 2019; 16: 299-310. doi: 10.22034/IJI.2019.80281
  • 9. Sumita Y, Murakawa Y, Sugiura T, Wada Y, Nagai A et al. Elevated BAFF levels in the cerebrospinal fluid of patients with neuro-Behçet’s disease: BAFF is correlated with progressive dementia and psychosis. Scandinavian Journal of Immunology 2012; 75: 633-640. doi: 10.1111/j.1365-3083.2012.02694.x
  • 10. Akman-Demir G, Tüzün E, İçöz S, Yeşilot N, Yentür SP et al. Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine 2008; 44: 373-376. doi: 10.1016/j.cyto.2008.10.007
  • 11. Ramani S, Berard JA, Walker LAS. The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review. Journal of the Neurological Sciences 2021; 420: 117229. doi: 10.1016/j.jns.2020.117229
  • 12. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L et al. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery, and Psychiatry 2019; 90: 870-881. doi: 10.1136/jnnp-2018-320106
  • 13. Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-1093. doi: 10.1093/brain/awq035
  • 14. Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K et al. The glial marker YKL-40 is decreased in synucleinopathies. Movement Disorders: Official Journal of the Movement Disorder Society 2013; 28: 1882-1885. doi: 10.1002/mds.25589
  • 15. Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis 2015; 21: 1251-1261. doi: 10.1177/1352458514561906
  • 16. Lopalco G, Lucherini OM, Lopalco A, Venerito V, Fabiani C et al. Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease. Frontiers in Immunology 2017; 8: 200. doi: 10.3389/ fimmu.2017.00200
  • 17. Bilen H, Altınkaynak K, Şebin E, Aksoy H, Akçay F. Serum YKL-40 and MDA levels in Behçet disease. The Journal of the Pakistan Medical Association 2016; 66: 1299-1302
  • 18. Seo J, Ahn Y, Zheng Z, Kim BO, Choi MJ et al. Clinical significance of serum YKL-40 in Behçet disease. The British Journal of Dermatology 2016; 174: 1337-1344.
  • 19. Timirci-Kahraman O, Karaaslan Z, Tüzün E, Kürtüncü M, Baykal AT et al. Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid. Acta Neurologica Belgica 2019; 119: 101-111. doi: 10.1007/s13760-018-0954-4
  • 20. Tamam Y, Güneş B, Akbayır E, Kızılay T, Karaaslan Z et al. CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 2020; 48: 102697. doi: 10.1016/j.msard.2020.102697
  • 21. Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ et al. Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation. Immunity 1997; 6: 13-22. doi: 10.1016/ s1074-7613(00)80238-1
  • 22. Lindblad O, Chougule RA, Moharram SA, Kabir NN, Sun J et al. The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochemical and Biophysical Research Communications 2015; 467: 742-747. doi: 10.1016/j.bbrc.2015.10.071
  • 23. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990; 335:1078-1080.
  • 24. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. Journal of Neuroinflammation 2010; 7: 34. doi: 10.1186/1742-2094-7-34
  • 25. Uğurel E, Erdağ E, Küçükali Cİ, Olcay A, Şanlı E et al. Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-Behçet’s Disease. In Vivo 2019; 33: 1493- 1497. doi: 10.21873/invivo.11629
  • 26. Kim EH, Park MJ, Park S, Lee ES. Increased expression of the NLRP3 inflammasome components in patients with Behçet’s disease. Journal of Inflammation (London, England) 2015; 12: 41. doi:10.1186/s12950-015-0086-z
  • 27. Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A et al. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology 2019; 266: 2157-2163. doi: 10.1007/s00415-019-09398-7
  • 28. Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Multiple Sclerosis 2020; 26: 1670-1781. doi: 10.1177/1352458519881428
  • 29. Moses Alder N, Fisher M, Yazıcı Y. Behçet’s syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clinical and Experimental Rheumatology 2008; 26: S110-113.
  • 30. Mumcu G, İnanç N, Yavuz S, Direskeneli H. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet’s disease. Clinical and Experimental Rheumatology 2007; 25: S27-33.
  • 31. Gündüz T, Kürtüncü M, Matur Z, Tüzün E, Limon U et al. Laboratory and clinical correlates of brain atrophy in Neuro- Behçet’s disease. Journal of the Neurological Sciences 2020; 414: 116831. doi: 10.1016/j.jns.2020.116831
  • 32. Yeşilot N, Shehu M, Öktem-Tanör O, Serdaroğlu P, Akman- Demir G. Silent neurological involvement in Behçet’s disease. Clinical and Experimental Rheumatology 2006; 24 (5 Suppl 42): S65-70.
  • 33. Barros C, Fernandes A. Linking Cognitive Impairment to Neuroinflammation in Multiple Sclerosis using neuroimaging tools. Multiple Sclerosis and Related Disorders 2020; 47: 102622. doi: 10.1016/j.msard.2020.102622
  • 34. Jiang D, Gong F, Ge X, Lv C, Huang C et al. Neuron-derived exosomes-transmitted miR-124-3p protect traumatically injured spinal cord by suppressing the activation of neurotoxic microglia and astrocytes. Journal of Nanobiotechnology 2020; 18: 105. doi: 10.1186/s12951-020-00665-8
APA Karaaslan Z, Şanlı E, Timirci-Kahraman O, YILMAZ V, Akbayır E, Koral G, içöz s, GÜNDÜZ T, Kucukali C, Kürtüncü M, Tuzun E (2022). Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. , 1266 - 1273. 10.55730/1300-0144.5432
Chicago Karaaslan Zerrin,Şanlı Elif,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,Akbayır Ece,Koral Gizem,içöz sema,GÜNDÜZ TUNCAY,Kucukali Cem Ismail,Kürtüncü Murat,Tuzun Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. (2022): 1266 - 1273. 10.55730/1300-0144.5432
MLA Karaaslan Zerrin,Şanlı Elif,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,Akbayır Ece,Koral Gizem,içöz sema,GÜNDÜZ TUNCAY,Kucukali Cem Ismail,Kürtüncü Murat,Tuzun Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. , 2022, ss.1266 - 1273. 10.55730/1300-0144.5432
AMA Karaaslan Z,Şanlı E,Timirci-Kahraman O,YILMAZ V,Akbayır E,Koral G,içöz s,GÜNDÜZ T,Kucukali C,Kürtüncü M,Tuzun E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. . 2022; 1266 - 1273. 10.55730/1300-0144.5432
Vancouver Karaaslan Z,Şanlı E,Timirci-Kahraman O,YILMAZ V,Akbayır E,Koral G,içöz s,GÜNDÜZ T,Kucukali C,Kürtüncü M,Tuzun E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. . 2022; 1266 - 1273. 10.55730/1300-0144.5432
IEEE Karaaslan Z,Şanlı E,Timirci-Kahraman O,YILMAZ V,Akbayır E,Koral G,içöz s,GÜNDÜZ T,Kucukali C,Kürtüncü M,Tuzun E "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease." , ss.1266 - 1273, 2022. 10.55730/1300-0144.5432
ISNAD Karaaslan, Zerrin vd. "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease". (2022), 1266-1273. https://doi.org/10.55730/1300-0144.5432
APA Karaaslan Z, Şanlı E, Timirci-Kahraman O, YILMAZ V, Akbayır E, Koral G, içöz s, GÜNDÜZ T, Kucukali C, Kürtüncü M, Tuzun E (2022). Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences, 52(4), 1266 - 1273. 10.55730/1300-0144.5432
Chicago Karaaslan Zerrin,Şanlı Elif,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,Akbayır Ece,Koral Gizem,içöz sema,GÜNDÜZ TUNCAY,Kucukali Cem Ismail,Kürtüncü Murat,Tuzun Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences 52, no.4 (2022): 1266 - 1273. 10.55730/1300-0144.5432
MLA Karaaslan Zerrin,Şanlı Elif,Timirci-Kahraman Ozlem,YILMAZ VUSLAT,Akbayır Ece,Koral Gizem,içöz sema,GÜNDÜZ TUNCAY,Kucukali Cem Ismail,Kürtüncü Murat,Tuzun Erdem Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1266 - 1273. 10.55730/1300-0144.5432
AMA Karaaslan Z,Şanlı E,Timirci-Kahraman O,YILMAZ V,Akbayır E,Koral G,içöz s,GÜNDÜZ T,Kucukali C,Kürtüncü M,Tuzun E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences. 2022; 52(4): 1266 - 1273. 10.55730/1300-0144.5432
Vancouver Karaaslan Z,Şanlı E,Timirci-Kahraman O,YILMAZ V,Akbayır E,Koral G,içöz s,GÜNDÜZ T,Kucukali C,Kürtüncü M,Tuzun E Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease. Turkish Journal of Medical Sciences. 2022; 52(4): 1266 - 1273. 10.55730/1300-0144.5432
IEEE Karaaslan Z,Şanlı E,Timirci-Kahraman O,YILMAZ V,Akbayır E,Koral G,içöz s,GÜNDÜZ T,Kucukali C,Kürtüncü M,Tuzun E "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease." Turkish Journal of Medical Sciences, 52, ss.1266 - 1273, 2022. 10.55730/1300-0144.5432
ISNAD Karaaslan, Zerrin vd. "Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Behçet’s disease". Turkish Journal of Medical Sciences 52/4 (2022), 1266-1273. https://doi.org/10.55730/1300-0144.5432